Wld S but not Nmnat1 protects dopaminergic neurites from MPP + neurotoxicity

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Antenor Dorsey, Jo Ann V ^a   O'Malley, Karen L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

axonal degeneration; dopaminergic neurons; MPP +; Nmnat1; Parkinson's disease; Wld S

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; HYBRID PROTEIN; NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE; UNCLASSIFIED DRUG; WALLERIAN DEGENERATION SLOW FUSION PROTEIN; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; NMNAT1 PROTEIN, MOUSE; WLD PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; LENTIVIRINAE; MOUSE; NERVE FIBER; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN FUNCTION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; MUTATION; NERVE DEGENERATION; NEURITE; PARKINSON DISEASE; PHYSIOLOGY; TRANSGENIC MOUSE; ULTRASTRUCTURE;

MUS; PARKINSONIA; WALLERIA;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; AXONS; CELLS, CULTURED; DOPAMINERGIC NEURONS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; NAD; NERVE TISSUE PROTEINS; NEURITES; NEUROPROTECTIVE AGENTS; NICOTINAMIDE-NUCLEOTIDE ADENYLYLTRANSFERASE; PARKINSON DISEASE; WALLERIAN DEGENERATION;

EID: 84856608720     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-5     Document Type: Article

References (75)

1. Parkinson's disease: mechanisms and models. Dauer W, Przedborski S, Neuron 2003 39 889 909 10.1016/S0896-6273(03)00568-3 12971891 (Pubitemid 37130207)
2. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM, Prog Neurobiol 2001 65 135 172 10.1016/S0301-0082(01)00003-X 11403877 (Pubitemid 32524182)
3. Stages in the development of Parkinson's disease-related pathology. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K, Cell Tissue Res 2004 318 121 134 10.1007/s00441-004-0956-9 15338272 (Pubitemid 39362633)
4. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F, J Neurol Sci 1973 20 415 455 10.1016/0022-510X(73)90175-5 4272516
5. Striatal dopamine deficiency in Parkinson's disease: role of aging. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y, Ann Neurol 1989 26 551 557 10.1002/ana.410260409 2817829 (Pubitemid 19247232)
6. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. Riederer P, Wuketich S, J Neural Transm 1976 38 277 301 10.1007/BF01249445 956814
7. Clinical progression in Parkinson disease and the neurobiology of axons. Cheng HC, Ulane CM, Burke RE, Ann Neurol 2010 67 715 725 10.1002/ana.21995 20517933
8. Ageing and Parkinson's disease: substantia nigra regional selectivity. Fearnley JM, Lees AJ, Brain 1991 114 Pt 5 2283 2301 1933245
9. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. Kramer ML, Schulz-Schaeffer WJ, J Neurosci 2007 27 1405 1410 10.1523/JNEUROSCI.4564-06.2007 17287515
10. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. Saha AR, Hill J, Utton MA, Asuni AA, Ackerley S, Grierson AJ, Miller CC, Davies AM, Buchman VL, Anderton BH, Hanger DP, J Cell Sci 2004 117 1017 1024 10.1242/jcs.00967 14996933 (Pubitemid 38456084)
11. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C, Nat Neurosci 2009 12 826 828 10.1038/nn.2349 19503083
12. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N, Nature 1998 392 605 608 10.1038/33416 9560156 (Pubitemid 28207717)
13. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Weihofen A, Thomas KJ, Ostaszewski BL, Cookson MR, Selkoe DJ, Biochemistry 2009 48 2045 2052 10.1021/bi8019178 19152501
14. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Mortiboys H, Thomas KJ, Koopman WJ, Klaffke S, Abou-Sleiman P, Olpin S, Wood NW, Willems PH, Smeitink JA, Cookson MR, Bandmann O, Ann Neurol 2008 64 555 565 10.1002/ana.21492 19067348
15. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. Ren Y, Liu W, Jiang H, Jiang Q, Feng J, J Biol Chem 2005 280 34105 34112 10.1074/jbc.M503483200 16091364 (Pubitemid 41443134)
16. Microtubule assembly is directly affected by MPP(+)in vitro. Cappelletti G, Pedrotti B, Maggioni MG, Maci R, Cell Biol Int 2001 25 981 984 10.1006/cbir.2001.0772 11589612 (Pubitemid 32977046)
17. Microtubule dysfunction precedes transport impairment and mitochondria damage in MPP+ -induced neurodegeneration. Cartelli D, Ronchi C, Maggioni MG, Rodighiero S, Giavini E, Cappelletti G, J Neurochem 2010 115 247 258 10.1111/j.1471-4159.2010.06924.x 20649848
18. 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Morfini G, Pigino G, Opalach K, Serulle Y, Moreira JE, Sugimori M, Llinas RR, Brady ST, Proc Natl Acad Sci USA 2007 104 2442 2447 10.1073/pnas.0611231104 17287338 (Pubitemid 46391416)
19. The Parkinsonian Mimetic, MPP+, Specifically Impairs Mitochondrial Transport in Dopamine Axons. Kim-Han JS, Antenor-Dorsey JA, O'Malley KL, J Neurosci 2011 31 7212 7221 10.1523/JNEUROSCI.0711-11.2011 21562285
20. Wallerian degeneration, wld(s), and nmnat. Coleman MP, Freeman MR, Annu Rev Neurosci 2010 33 245 267 10.1146/annurev-neuro-060909-153248 20345246
21. The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice. Mi W, Beirowski B, Gillingwater TH, Adalbert R, Wagner D, Grumme D, Osaka H, Conforti L, Arnhold S, Addicks K, Wada K, Ribchester RR, Coleman MP, Brain 2005 128 405 416 15644421 (Pubitemid 40222609)
22. Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Sajadi A, Schneider BL, Aebischer P, Curr Biol 2004 14 326 330 14972684 (Pubitemid 38300211)
23. Wld(S) mice are protected against the Parkinsonian mimetic MPTP. Hasbani DM, O'Malley KL, Exp Neurol 2006 202 93 99 10.1016/j.expneurol.2006.05.017 16806180 (Pubitemid 44344251)
24. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D, Thomson D, Gillingwater T, Court F, Conforti L, Fernando FS, Tarlton A, Andressen C, Addicks K, Magni G, Ribchester RR, Perry VH, Coleman MP, Nat Neurosci 2001 4 1199 1206 11770485 (Pubitemid 33135625)
25. An 85-kb tandem triplication in the slow Wallerian degeneration (Wlds) mouse. Coleman MP, Conforti L, Buckmaster EA, Tarlton A, Ewing RM, Brown MC, Lyon MF, Perry VH, Proc Natl Acad Sci USA 1998 95 9985 9990 10.1073/pnas.95.17. 9985 9707587 (Pubitemid 28415281)
26. Wld S protein requires Nmnat activity and a short N-terminal sequence to protect axons in mice. Conforti L, Wilbrey A, Morreale G, Janeckova L, Beirowski B, Adalbert R, Mazzola F, Di Stefano M, Hartley R, Babetto E, Smith T, Gilley J, Billington RA, Genazzani AA, Ribchester RR, Magni G, Coleman M, J Cell Biol 2009 184 491 500 10.1083/jcb.200807175 19237596
27. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Araki T, Sasaki Y, Milbrandt J, Science 2004 305 1010 1013 10.1126/science.1098014 15310905 (Pubitemid 39071777)
28. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. Sasaki Y, Araki T, Milbrandt J, J Neurosci 2006 26 8484 8491 10.1523/JNEUROSCI.2320-06.2006 16914673 (Pubitemid 44316176)
29. WldS requires Nmnat1 enzymatic activity and N16-VCP interactions to suppress Wallerian degeneration. Avery MA, Sheehan AE, Kerr KS, Wang J, Freeman MR, J Cell Biol 2009 184 501 513 10.1083/jcb.200808042 19237597
30. NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Zhai RG, Zhang F, Hiesinger PR, Cao Y, Haueter CM, Bellen HJ, Nature 2008 452 887 891 10.1038/nature06721 18344983 (Pubitemid 351550857)
31. Nmnat exerts neuroprotective effects in dendrites and axons. Wen Y, Parrish JZ, He R, Zhai RG, Kim MD, Mol Cell Neurosci 2011
32. Drosophila NMNAT maintains neural integrity independent of its NAD synthesis activity. Zhai RG, Cao Y, Hiesinger PR, Zhou Y, Mehta SQ, Schulze KL, Verstreken P, Bellen HJ, PLoS Biol 2006 4 416 10.1371/journal.pbio.0040416 17132048 (Pubitemid 44917622)
33. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. Lotharius J, Dugan LL, O'Malley KL, J Neurosci 1999 19 1284 1293 9952406 (Pubitemid 29088911)
34. Targeting NMNAT1 to axons and synapses transforms its neuroprotective potency in vivo. Babetto E, Beirowski B, Janeckova L, Brown R, Gilley J, Thomson D, Ribchester RR, Coleman MP, J Neurosci 2010 30 13291 13304 10.1523/JNEUROSCI.1189-10.2010 20926655
35. Axonal degeneration is blocked by nicotinamide mononucleotide adenylyltransferase (Nmnat) protein transduction into transected axons. Sasaki Y, Milbrandt J, J Biol Chem 2010 285 41211 41215 10.1074/jbc.C110.193904 21071441
36. Nmnat delays axonal degeneration caused by mitochondrial and oxidative stress. Press C, Milbrandt J, J Neurosci 2008 28 4861 4871 10.1523/JNEUROSCI. 0525-08.2008 18463239
37. Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. Verghese PB, Sasaki Y, Yang D, Stewart F, Sabar F, Finn MB, Wroge CM, Mennerick S, Neil JJ, Milbrandt J, Holtzman DM, Proc Natl Acad Sci USA 2011 108 19054 19059 10.1073/pnas.1107325108 22058226
38. Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. Sasaki Y, Vohra BP, Lund FE, Milbrandt J, J Neurosci 2009 29 5525 5535 10.1523/JNEUROSCI.5469-08.2009 19403820
39. Transgenic mice expressing the Nmnat1 protein manifest robust delay in axonal degeneration in vivo. Sasaki Y, Vohra BP, Baloh RH, Milbrandt J, J Neurosci 2009 29 6526 6534 10.1523/JNEUROSCI.1429-09.2009 19458223
40. Modified cell cycle status in a mouse model of altered neuronal vulnerability (slow Wallerian degeneration; Wlds). Wishart TM, Pemberton HN, James SR, McCabe CJ, Gillingwater TH, Genome Biol 2008 9 101 10.1186/gb-2008-9-6-r101 18570652 (Pubitemid 352044829)
41. Nmnat2 delays axon degeneration in superior cervical ganglia dependent on its NAD synthesis activity. Yan T, Feng Y, Zheng J, Ge X, Zhang Y, Wu D, Zhao J, Zhai Q, Neurochem Int 2010 56 101 106 10.1016/j.neuint.2009.09.007 19778564
42. NAD(+) and axon degeneration revisited: Nmnat1 cannot substitute for Wld(S) to delay Wallerian degeneration. Conforti L, Fang G, Beirowski B, Wang MS, Sorci L, Asress S, Adalbert R, Silva A, Bridge K, Huang XP, Magni G, Glass JD, Coleman MP, Cell Death Differ 2007 14 116 127 10.1038/sj.cdd.4401944 16645633 (Pubitemid 44911899)
43. Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration. Yahata N, Yuasa S, Araki T, J Neurosci 2009 29 6276 6284 10.1523/JNEUROSCI.4304-08.2009 19439605
44. Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. Kaneko S, Wang J, Kaneko M, Yiu G, Hurrell JM, Chitnis T, Khoury SJ, He Z, J Neurosci 2006 26 9794 9804 10.1523/JNEUROSCI.2116-06.2006 16988050 (Pubitemid 44427718)
45. Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model. Yang J, Klaidman LK, Chang ML, Kem S, Sugawara T, Chan P, Adams JD, Pharmacol Biochem Behav 2002 73 901 910 10.1016/S0091-3057(02)00939-5 12213537 (Pubitemid 35246240)
46. Delayed treatment with nicotinamide (vitamin B3) reduces the infarct volume following focal cerebral ischemia in spontaneously hypertensive rats, diabetic and non-diabetic Fischer 344 rats. Sakakibara Y, Mitha AP, Ayoub IA, Ogilvy CS, Maynard KI, Brain Res 2002 931 68 73 10.1016/S0006-8993(02)02263-1 11897090 (Pubitemid 34230532)
47. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. Demarin V, Podobnik SS, Storga-Tomic D, Kay G, Drugs Exp Clin Res 2004 30 27 33 15134388 (Pubitemid 38560227)
48. Nicotinamide adenine dinucleotide (NADH) - a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Birkmayer JG, Vrecko C, Volc D, Birkmayer W, Acta Neurol Scand Suppl 1993 146 32 35 8101414 (Pubitemid 23251606)
49. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Birkmayer JG, Ann Clin Lab Sci 1996 26 1 9 8834355
50. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. Kuhn W, Muller T, Winkel R, Danielczik S, Gerstner A, Hacker R, Mattern C, Przuntek H, J Neural Transm 1996 103 1187 1193 10.1007/BF01271203 9013405 (Pubitemid 26381979)
51. Nicotinamide/nicotinic acid mononucleotide adenylyltransferase, new insights into an ancient enzyme. Zhai RG, Rizzi M, Garavaglia S, Cell Mol Life Sci 2009 66 2805 2818 10.1007/s00018-009-0047-x 19448972
52. Nicotinamide Mononucleotide Adenylyltransferase Is a Stress Response Protein Regulated by the Heat Shock Factor/Hypoxia-inducible Factor 1 Pathway. Ali YO, McCormack R, Darr A, Zhai RG, J Biol Chem 2011 286 19089 19099 10.1074/jbc.M111.219295 21478149
53. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2,5,6-tetrahydropyridine. Nicklas WJ, Vyas I, Heikkila RE, Life Sci 1985 36 2503 2508 10.1016/0024-3205(85)90146-8 2861548 (Pubitemid 15072756)
54. Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. Ramsay RR, Krueger MJ, Youngster SK, Gluck MR, Casida JE, Singer TP, J Neurochem 1991 56 1184 1190 10.1111/j.1471-4159.1991.tb11409.x 2002336 (Pubitemid 21902034)
55. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Ramsay RR, Salach JI, Singer TP, Biochem Biophys Res Commun 1986 134 743 748 10.1016/S0006-291X(86)80483-1 2868716 (Pubitemid 16070558)
56. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. Lotharius J, O'Malley KL, J Biol Chem 2000 275 38581 38588 10969076 (Pubitemid 32009186)
57. The mechanism of action of MPTP and MPP+ on endogenous dopamine release from the rat corpus striatum superfused in vitro. Chang GD, Ramirez VD, Brain Res 1986 368 134 140 10.1016/0006-8993(86)91050-4 3485463 (Pubitemid 16052318)
58. The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor. Cappelletti G, Surrey T, Maci R, FEBS Lett 2005 579 4781 4786 10.1016/j.febslet.2005.07.058 16098973 (Pubitemid 41218663)
59. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Zhu JH, Horbinski C, Guo F, Watkins S, Uchiyama Y, Chu CT, Am J Pathol 2007 170 75 86 10.2353/ajpath.2007.060524 17200184 (Pubitemid 47339191)
60. Axonal degeneration is mediated by the mitochondrial permeability transition pore. Barrientos SA, Martinez NW, Yoo S, Jara JS, Zamorano S, Hetz C, Twiss JL, Alvarez J, Court FA, J Neurosci 2011 31 966 978 10.1523/JNEUROSCI. 4065-10.2011 21248121
61. Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Wishart TM, Paterson JM, Short DM, Meredith S, Robertson KA, Sutherland C, Cousin MA, Dutia MB, Gillingwater TH, Mol Cell Proteomics 2007 6 1318 1330 10.1074/mcp.M600457-MCP200 17470424 (Pubitemid 47365431)
62. A dual leucine kinase-dependent axon self-destruction program promotes Wallerian degeneration. Miller BR, Press C, Daniels RW, Sasaki Y, Milbrandt J, DiAntonio A, Nat Neurosci 2009 12 387 389 10.1038/nn.2290 19287387
63. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. Surjana D, Halliday GM, Damian DL, J Nucleic Acids 2010 2010
64. Transcriptional regulation of neuronal genes and its effect on neural functions: NAD-dependent histone deacetylase SIRT1 (Sir2). Hisahara S, Chiba S, Matsumoto H, Horio Y, J Pharmacol Sci 2005 98 200 204 10.1254/jphs.FMJ05001X2 16006743 (Pubitemid 41296398)
65. A local mechanism mediates NAD-dependent protection of axon degeneration. Wang J, Zhai Q, Chen Y, Lin E, Gu W, McBurney MW, He Z, J Cell Biol 2005 170 349 355 10.1083/jcb.200504028 16043516 (Pubitemid 41126935)
66. Neuroprotection after transient global cerebral ischemia in Wld(s) mutant mice. Gillingwater TH, Haley JE, Ribchester RR, Horsburgh K, J Cereb Blood Flow Metab 2004 24 62 66 14688617 (Pubitemid 38021269)
67. Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Ferri A, Sanes JR, Coleman MP, Cunningham JM, Kato AC, Curr Biol 2003 13 669 673 10.1016/S0960-9822(03)00206-9 12699624 (Pubitemid 36453316)
68. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Liang CL, Wang TT, Luby-Phelps K, German DC, Exp Neurol 2007 203 370 380 10.1016/j.expneurol.2006.08.015 17010972 (Pubitemid 46149588)
69. The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease. Hastings TG, J Bioenerg Biomembr 2009 41 469 472 10.1007/s10863-009-9257-z 19967436
70. What causes the death of dopaminergic neurons in Parkinson's disease? Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA, Prog Brain Res 2010 183 59 77 20696315
71. Neuropathology of non-motor features of Parkinson disease. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE, Parkinsonism Relat Disord 2009 15 Suppl 3 1 5 20882687
72. 6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death. Bernstein AI, Garrison SP, Zambetti GP, O'Malley KL, Mol Neurodegener 2011 6 2 10.1186/1750-1326-6-2 21211034
73. Non-nuclear Wld(S) determines its neuroprotective efficacy for axons and synapses in vivo. Beirowski B, Babetto E, Gilley J, Mazzola F, Conforti L, Janeckova L, Magni G, Ribchester RR, Coleman MP, J Neurosci 2009 29 653 668 10.1523/JNEUROSCI.3814-08.2009 19158292
74. Dorsal root ganglion neurons react to semaphorin 3A application through a biphasic response that requires multiple myosin II isoforms. Brown JA, Wysolmerski RB, Bridgman PC, Mol Biol Cell 2009 20 1167 1179 10.1091/mbc.E08-01-0065 19109430
75. Enzymology of NAD+ homeostasis in man. Magni G, Amici A, Emanuelli M, Orsomando G, Raffaelli N, Ruggieri S, Cell Mol Life Sci 2004 61 19 34 10.1007/s00018-003-3161-1 14704851 (Pubitemid 38121897)